title: [Characteristics of etiotropic therapy of plaque infection induced by atypical strains of F1- phenotype plaque microbe].
abstract: The efficacy of various group antibacterial drugs: aminoglycosides, quinolones, 3rd generation cephalosporins, doxycycline, rifampicin, ampicillin and azthreonam was estimated in the treatment of experimental plague of albino mice induced by antigen complete and atypical strains of the F1- phenotype plague microbe. The in vitro experiments showed that all the strains of the plague microbe irrespective of the phenotype (F1+ or F1-) were highly susceptible to the drugs. The animal experiments demonstrated that aminoglycosides (streptomycin, kanamycin, tobramycin, gentamicin and amikacin) and cephalosporins (ceftriaxone and ceftazidim) were highly efficient in the prophylaxis and treatment of plague due to F1+ and F1- strains. In experimental plague due to F1- phenotype plague microbe the prophylactic effects of cefotaxime, cefoperazone, sulbactam/ampicillin, azthreonam, ciprofloxacin and rifampicin were lower. However, increase of the daily doses of the drugs and prolongation of the treatment course up to 7 days made it possible to increase the protective effects up to 80-100 per cent. Doxycycline and ampicillin were not sufficiently efficient even when used for 10 days in the prophylaxis of plague due to F1- strains.
authors.affiliation: Research Plague Institute, Rostov-on-Don.
authors.forename: I V
authors.initials: IV
authors.lastname: Ryzhko
authors.forename: E D
authors.initials: ED
authors.lastname: Samokhodkina
authors.forename: R I
authors.initials: RI
authors.lastname: Tsuraeva
authors.forename: A I
authors.initials: AI
authors.lastname: Shcherbaniuk
authors.forename: N S
authors.initials: NS
authors.lastname: Tsetskhladze
mesh_terms: D000617:Aminoglycosides; D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D000942:Antigens, Bacterial / Q000276:immunology*; D001398:Aztreonam / Q000494:pharmacology / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000276:immunology*; D002511:Cephalosporins / Q000494:pharmacology; D004195:Disease Models, Animal; D004318:Doxycycline / Q000494:pharmacology; D024841:Fluoroquinolones; D051379:Mice; D008997:Monobactams / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D010641:Phenotype; D010930:Plague / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control*; D012293:Rifampin / Q000494:pharmacology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D002511:Cephalosporins; D024841:Fluoroquinolones; D008997:Monobactams; D010406:Penicillins; C086725:caf1 protein, Yersinia pestis; D000667:Ampicillin; D001398:Aztreonam; D004318:Doxycycline; D012293:Rifampin